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Abstract
Metallothionein (MT) is a small, cysteine-rich protein with significant
immunomodulatory activity. It has been shown to play a critical role in important cellular
mechanisms including heavy metal detoxification, essential metal management and the
inflammatory response. MT production can be induced by a number of cellular stressors
and acts to lessen the harmful effects of oxidizing agents and heavy metal exposure.
Previous studies have shown that the dose of the metallothionein gene present in an
individual may have significant effects on the adaptive immune response, yet the
mechanism behind this phenomenon remains unknown. We hypothesize that the gene
dose of metallothionein will significantly affect the lympholiferative response between
three mouse strains that produce different amounts of metallothionein due to genetic
manipulation. Our results suggest that deviations from the normal gene dose of MT affect
the speed and degree of a lymphoproliferative response; for example, MTKO produces a
more robust response than either the MT-TGN or WT strains. Further investigation is
needed to determine whether the hyperproliferation of the knockout (MTKO) murine
strain is a result of increased oxidative stress and damage due to the lack of functional
metallothionein. The means by which MTKO lymphocytes respond more robustly to
proliferative stimulation may prove significant in contributing to the body of knowledge
regarding the mechanisms of autoimmune disease development and it’s therapeutic
management. Insight into these MT gene disparities may help lay the groundwork for
future treatments and therapies.
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Introduction
The Mechanisms of Autoimmune Disease
Autoimmune diseases affect more than 23 million Americans, with direct
healthcare costs totaling over 100 billion dollars annually [45]. These disorders are
caused by an inappropriate immune response against self-antigens; the body begins
mounting an immunological attack against it’s own cells, often resulting in debilitating
physiological conditions. The most common treatment for autoimmune disorders is
immunosuppression, in which medication is used to decrease the immune response.
However, traditional methods of immunosuppresion often involve chemicals and
radiation that leave the patient immunocompromised and susceptible to a wide range of
opportunistic infections, an outcome also seen in patients undergoing chemotherapy.
Dysregulation of the immune system can lead to both autoimmune and
inflammatory disorders. In the case of autoimmunity, the immune system becomes
activated by the body’s own antigens whereas inflammatory disorders result from an
inappropriately large reaction to non-self antigens and the downstream effects. The body
has its own mechanisms for up-regulating or down-regulating the different facets of the
immune system as needed. If we can elucidate some of the mechanisms by which the
body naturally manages autoimmunity, we may discover novel therapeutic agents for
autoimmune conditions.
During invasion by a foreign antigen, there are two different components of the
immune system that react in order to protect the host. Innate immunity, the first response,
discriminates between self and non-self. Activation of the innate immune system causes
the expression of co-stimulatory molecules on phagocytic cells, which allows activation
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of adaptive immunity. The adaptive part of the immune response is comprised of
lymphocytes and macrophages, which can sense and eradicate foreign antigens like
viruses, bacteria or improperly transformed host cells.
The immune response involves many signal cascade pathways and can be altered
by a wide variety of mechanisms. Heavy metal exposure, radiation and stress can change
the equilibrium of the immune system [6]. Depending on the circumstances and type of
stress, prolonged periods can lead to immune suppression and others can lead to
inappropriate immune activations like autoimmune disease.
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Metallothionein as a Stress Response Protein
Metallothionein (MT) was first characterized in 1957 as a cadmium-binding
protein [1]. There are four major isoforms of mammalian MT; MT1 and MT2 are present
at basal levels in all mammalian tissues during all stages of development, while MT3 and
MT4 are found largely in glutaminergic neurons and stratified squamous epithelial cells,
respectively[2, 3].
Metallothionein is an unusually low molecular weight protein (~7 kDa) with an
amino acid sequence roughly 60-70 amino acids in length. All known forms of MT
contain approximately 20 conserved cysteine residues and five or more conserved lysine
residues (MT-1 and 2 each have eight lysines) [4]. MT is most commonly found
associated with Zn and it can also bind a wide variety of other essential and toxic metals,
including copper, cadmium and mercury. Various cysteine-binding motifs are responsible
for its strong affinity for these transition metals; NMR spectroscopy and X-ray
crystallography show that the folded protein consists of an alpha and beta domain with
cysteines organized in “clusters”, enabling it to bind up to seven zinc atoms [5]. This high
affinity for metals contributes to metallothionein’s role as a stress response protein and
enables it to protect cells from damage caused by toxic heavy metal cations [6].
Metallothionein is believed to play a role in several important “housekeeping”
functions within the cell, including oxidation-reduction equilibrium, transcription factor
activation and the regulation of essential metals within the cell [7]. Metallothionein has
been shown to control the amount of zinc available in cells and participates in the transfer
of essential metal ions to critical stress response proteins and transcription factors such as
zinc-finger proteins, apoenzymes and other metalloproteins [8, 9].
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Metallothioneins are often categorized as stress-response proteins because they
can be induced by various cellular stressors including glucocorticoid stress, hormones,
acute phase cytokines, endotoxin, heavy metals, interferon and reactive oxygen and
nitrogen species [10-15]. During heavy metal exposure, divalent metal cations will react
with components of host cells, causing widespread damage. Binding of MT to cadmium
has been shown to increase cellular survival by sequestering heavy metals and
maintaining it in a less toxic complex form [16]. Mice that overexpress MT show
decreased morbidity and mortality when exposed to cadmium in their drinking water;
conversely, mice with a truncated, non-functional MT gene were more sensitive to this
heavy metal toxicity [16].
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Metallothionein Plays a Crucial Role In Cellular Homeostasis
There is a high percentage of sequence similarity between human and murine
metallothionein, indicating that the MT gene family is evolutionarily conserved and
performs important housekeeping functions within the cell. Because of the rapid rate and
varied induction of metallothionein up-regulation, we believe that the protein is involved
in many homeostatic processes throughout the cell. While MT-null mouse mutants
reproduce and develop normally, evidence suggests that MT synthesis impairment in
humans may be linked to some neurological disorders [17, 18]. This link indicates that
metallothionein might play an important role in metal management during human
development.
While the absence of a functional MT gene complement can be survived in
animals house in optimal conditions, research indicates that organisms that that possess
functional MT have a genetic advantage during times of physiological stress [16]. The
enhanced survival of organisms with an intact MT gene is believed to be due, in part, to
metallothionein’s role in the regulation of the immune system.
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Metallothionein Regulates Zinc Bioavailability
MT’s critical role in zinc bioavailability may indicate that it is an important
regulator of the immune response. The presence of zinc is required for many facets of the
immune response. Improper zinc management in humans has been associated with
decreased proliferation of lymphocytes, improper ratios of CD4+ and CD8+ T cells,
impaired natural killer cell activity and thymic atrophy [8]. All of these are critical
components of the immune response and may lead to inappropriate immune activation
and suppression. This leads us to believe that metallothionein may play an integral role in
the development, differentiation and apoptosis of important populations of immune cells.
Bacteria require the incorporation of zinc for gene expression, virulence and
metabolism, so it stands to reason that restricting available zinc might be an effective
method to slow bacterial growth during infection [19]. Studies have shown that proteins
that chelate or sequester zinc, like calprotectin and ZIP/Znt transporters can inhibit
bacterial growth [19,20]. This suggests that metallothionein may also act to sequester
essential zinc from microbial organisms during a bacterial infection.
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Metallothionein and the Neutralization of Reactive Species
One important component of the innate immune response is a phenomenon
known as a “respiratory burst”, in which macrophages and neutrophils release reactive
chemicals such as nitric oxide, hyderogen peroxide, hydroxyl radicals, hypochlorite and
superoxide anions during infection [20-23]. Although this defense mechanism is directed
at bacterial cells, it can also cause significant bystander damage to the host cells because
these reactive species are small enough to pass through host membranes [24]. The thiol
groups of metallothionein have the capability to bind and neutralize intracellular ROS,
conferring a protective effect to the host cells [23].
Chemicals that induce the formation of ROS and RNS can also up-regulate the
transcription of metallothionein genes. Current research indicates that the oxidation of
cellular ligands by ROS causes the release of zinc, which activates MTF-1, which can
then activate metallothionein gene transcription [25].This indicates that up-regulation of
MT during ROS exposure may serve to prevent host tissue damage and apoptosis. In
Alzheimer’s disease, a common neurodegenerative disorder, inflammation can lead to the
creation of reactive oxygen and nitrogen species that can damage neurons. Brain lesions
in Alzheimer’s patients have been linked to free radical bursts and it has been suggested
that changes in MT expression may lead to this intermittent radical up regulation and the
associated damage [26, 27]. MT has also been shown to have a protective role in
neuronal wound healing [47].
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The Immunomodulatory Functions of Metallothionein
The cysteines that are not involved in metal binding can participate in proteinprotein interactions; MT can bind to proteins found on the surface of T and B
lymphocytes, which may indicate a possible mechanism by which extracellular
metallothionein stimulates proliferation. Extracellular metallothionein has been shown to
stimulate modest levels of lymphoproliferation in murine splenocyte cultures and can act
synergistically with other cellular mitogens Concanavalin A (ConA) and
lipopolysaccharide (LPS) to produce a more robust proliferative response [28].
MT has been demonstrated to affect the apoptosis of cardiomyocytes by inhibiting
the p38 map kinase, a key component in the inflammatory response; this indicates that
MT may be involved in the regulation of inflammation and immune response signaling
[29]. Metallothionein mediates p53 activity by managing intracellular levels of metal and
reactive species [30]. High concentrations of MT decrease the movement of metals and
inhibit apoptosis through p53, which induces anti-apoptotic effect and has been used to
indicate cancer [31, 32]. MT may be a survival factor and may represent a potential
therapy for cancer cells that overexpress MT.
Metallothionein has also been implicated in the indirect regulation of transcription
factor activity. MT has been hypothesized to prevent the oxidation of IkB, modulating the
activation of NF:kB; control like this could have downstream effects on genes involved
in the immune response [33, 1]. The movement of MT into the nucleus during
differentiation is believed to be an important part of zinc ion delivery so DNA
transcription and replication can occur [35].
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Given that we believe that MT plays a key role in managing stress and normal
equilibrium within the body, it may also contribute to the normal immune response. If
MT is involved in the immune response, it may prove to be the link to stress-induced
changes in the immunity. Research has shown that mice with severe inflammatory
disease have very high levels of MT bound to circulating leukocytes. Knocking out the
MT genes for this mutation accelerates the disease and reduced the lifespan [36]. Patients
with auto immune disease of the connective tissue (like scleroderma and systemic lupus
erythematosus) and inflammatory rheumatic diseases like psoriatic arthritis, vasculitis
and rheumatoid arthritis have low levels of circulating copper bound MT compared to
control subjects. Injecting cortisones to increase levels of circulating Cu-MT produced
both clinical improvement and decreased inflammation [37].
Experiments have also been done with rat experimental autoimmune
encephalomyelitis (EAE) and MT-bound Zn II injections; results revealed a slowing of
the clinical progression and lethality of the disease [38]. It was accompanied by decreases
in IL-6 and TNF-a expression and leukocyte infiltration. The effects of MT injection on
the development and progression of collagen-induced arthritis in rats was also analyzed.
Injections of zinc (to induce MT) and MT-1 and 2 reduced the progression to arthritis;
indicating that MT also regulates immune cell activation [39].
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Metallothionein Gene Dose and the Immune Response
Several recent papers have explored the effects of MT gene dose on the immune
response. Mice that possess a targeted disruption of the Mt-1 and Mt-2 genes (MTKO)
were immunized with ovalbumin and were found to produce much higher levels of antiOVA antibody than their wild type counterparts [1]. Flow cytometry analysis of spleen
tissue from MTKO mice revealed an increase in the percentage of CD4+ and CD8+ Tcells, and these splenocytes were shown to be hyperproliferative in response to mitogen
stimulation.
It has been hypothesized that the lack of functional MT in the MTKO model
leaves the mouse less equipped to handle elevated levels of reactive oxygen species. This
increase in intracellular ROS leads to activation of transcription factors like NF-kB,
which augments the expression of immunomodulatory cytokines [1]. In essence, this lack
of endogenous MT creates a primed immune response that could potentially lead to
dangerous autoimmunities under stressful conditions.
Metallothionein has also been found to be a critical component of the pathogeninduced immune response [40]. Three congenic mouse strains were infected with Listeria
monocyogenes; the wild type C57BL/6 strain, the B6-MTKO knockout, and the B6MTTGN strain, which overexpresses metallothionein due to 112 extra copies of the Mt-1
gene. Surprisingly, both the transgenic and knockout strains were more resistant to
infection than the control C57BL/6; there appears to be a significant advantage to both
low and high gene doses of metallothionein when compared to the wild-type mice in this
particular biological context. In addition, MT gene dose has also been found to suppress
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the advance of rheumatoid arthritis in mice, pointing to the protein as a potential
opportunity for treatment of certain autoimmune diseases [41]. If the means by which
extreme levels of metallothionein affect the immune response can be characterized, it
may enable the development of more targeted therapies that will allow augmentation of a
patient’s innate immunity and suppression of debilitating autoimmune disorders.
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Proliferation as a Critical Catalyst in the Immune Response
For our research, we focused on the ability of metallothionein to scavenge free
radicals as the potential mechanism responsible for the hyperproliferation of MTKO
mice. The metal-thiolate clusters in metallothionein can be readily oxidized, thereby
neutralizing ROS and metallothionein can be as much as 100 times more effective than
glutathione in preventing cell damage by certain oxidation products [42].
We decided to examine the proliferative response because MT is believed to play
a critical role in cellular signaling, which is required for cell proliferation. Because
metallothionein has been shown as a reservoir for metals and a neutralizing force in
reactive species management, it suggests that MT may help to play a role in the events
leading up to and during an immune response. MT has been shown to facilitate the
activation of certain transcription factors that are activated by zinc. When human
macrophages where stimulated with LPS, it was found that MT expression was enhanced
[43]. When MT was down-regulated with anti-sense mRNA, LPS could no longer induce
a respiratory burst without harming cell viability [44].
Metallothionein may also act as a stimulation signal for lymphocytes. MT can
induce lymphoproliferation in vitro and acts synergistically with lymphocyte mitogens
like ConA and LPS to enhance proliferation. Interestingly, cells that are pre-treated with
MT are not sensitive to anti-proliferative agent N-ethyl maleimide, indicating that the
proliferative qualities of MT correlate with the levels of free thiols [28]. C3H/HeJ mice
have a defect in protein kinase C translocation, rendering them unresponsive to
stimulation with LPS. The addition of MT to these splenocytes in culture restores
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proliferation [28]. This suggests that MT may interact directly with membrane surface
proteins in order to effect signal transduction.
MT is believed to play a complex role in the immune response and normal
immune function and may represent a novel target for autoimmune disease therapies. The
experiments in this thesis focus on the immunological differences between animals that
possess a targeted gene disruption of the Mt1 and MT2 gene loci, the wild type and the
MT transgenic mouse that carries 112 extra copies of the extra Mt1 gene. The MTKO
mouse has been shown to have a sensitive to heavy metal and free-radical exposure, but
develops normally otherwise. In contrast, the MT-TGN mouse is less sensitive to heavy
metals. We hypothesize that the targeted gene disruption of the Mt1 and M2 sequences
will significantly alter the humoral immune response.
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Materials and Methods
Mouse Strains
All experiments utilized primary splenocytes from age and sex-matched from
C57BL6/J-MT1tm1Bri (MTKO), C57BL6/J-Tgn(Tm1)174Bri (MT-TGN) and C57BL/6
(WT) mice obtained from our own breeding stock kept at the AAALAC accredited
University of Connecticut vivarium. Animals were housed separately from other
colonies and were kept on a 12:12 hour light:dark cycle, with food and water available at
all times. The sentinel animals in this colony are serologically screened regularly and
were found to be free of common murine pathogens. The protocols for all of our
proposed experiments were approved by The University of Connecticut Institutional
Animal Care and Use Committee.

Media and Reagents
The M199 utilized for the cell proliferation assays was purchased from
GIBCO/BRL (Grand Island, NY). This media was supplemented with Fetal Bovine
Serum (FBS) from Hyclone (Logan, UT), 0.15% (w/v) sodium bicarbonate, 0.1mM nonessential amino acids, 1mM sodium pyruvate, 1mM L-glutamine and 50 ug/ml
gentamycin. Concanavalin A (ConA), bovine serum albumin (BSA) and
lipopolysaccharide (LPS, E.Coli) were purchased from Sigma Chemical (St. Louis, MO).

Splenocyte Preparation
To quantify the effects of differing amounts of endogenous metallothionein on
proliferation, splenocytes were obtained from all three mouse strains (WT, MT-TGN and
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MTKO). The spleens were aseptically prepared and placed in 3ml of M199 in a small
Petri dish. Spleens were then gently dissociated with flame-sterilized frosted slides. The
single cell suspension was the moved to a sterile tube and pelleted by centrifugation at
120 xg for 5 minutes. After decanting the supernatant, a hypotonic erythrocyte lysis was
conducted. The cells were then centrifuged again and resuspended in a final volume of
2ml complete M199 media.

Proliferation Assays
The cells were then plated in a 96-well cell culture-treated white
microfluorescence plate. 100ul of each cell suspension was added per well and the
unfractionated cells were cultured in the presence or absence of a polyclonal activator
(ConA or LPS). All samples in the proliferative assays were incubated at 37 degrees in a
special gas mixture (10% CO2, 7% O2, 83% N2) in order to reduce oxidative stress and
prolong cell survival. Proliferation was assayed at 24, 48 and 72 hours with the Promega
Cell Titer-Glo Assay, which utilizes luminescence to quantify cellular ATP levels as an
indication of cell population size. Luminescence was measured by a 96-well microplate
reader.
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Results
Optimization of Cell Quantification Assays
The proliferative assays were first attempted using Jurkat T-cells in order to
optimize the concentration of cells and the cellular mitogens LPS and ConA. This
optimization utilized the Promega 96 Aqueous Non-Radioactive Cell Proliferation Assay
(MTS), a colorimetric method for determining the number of viable cells in culture. The
MTS reagent is bioreduced by cells into a formazan product that can be measured at
490nm in a 96-well plate. This assay did not allow for the development of a satisfactory
cell number standard curve and Jurkat T-cells did not show measurable levels of
stimulation when dosed with Concanavalin A and LPS. An appreciable signal could not
be obtained from any cellular concentration (data now shown).
The MTS assay is often not suitable for lymphocytes since less of the formazan
product that is produced by mitochondria is produced in smaller amounts by
lymphocytes. In contrast, the Promega Cell Titer Glo Assay, which quantifies cellular
number based on the amount of available ATP, is compatible with lymphocyte
biochemistry. The Cell Titer Glo Assay yielded an optimal cell concentration of cultured
T-cells (100,000/well) and primary splenocytes (60,000/well); this cellular number was
large enough to produce a luminescent signal significantly above the background reading,
but still small enough that cellular viability was not negatively affected.

Optimization of Cellular Proliferation Assays
We next endeavored to find the optimal concentration of cellular mitogens (ConA
or LPS) to treat cells. When the concentration was too low (2.5ug/ml ConA in PBS),
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there was no appreciable difference between the luminescence of the control cells (treated
with PBS only) and that of the treated cells. When the concentration was too high
(10ug/ml ConA in PBS), there was a reduction in the level of luminescence; we
hypothesize that this is due to the cross-linking activation of the mitogens, which may
have caused cellular clumping and restricted nutrient availability, causing cell death.
Dosing the cells with 5ug/ml of ConA or LPS for 24 hours seemed to yield optimal
results and was chosen as the standard stimulation concentration.

The Proliferative Response of Mouse Strains with Different Numbers of MT1 and MT2
Gene Copies
In these experiments, splenocytes from each strain were isolated and stimulated
with Concanavalin A (ConA) during a three-day incubation, in which proliferation was
assayed at different time points (Fig 3). Twenty-four hours post-stimulation, MTKO cells
showed the highest levels of proliferation, yet after forty-eight hours, the MTKO
proliferative response had fallen far behind the other strains, indicating that their lack of
metallothionein may put them at a disadvantage after the initial primed response. In
addition, when the ConA dosage was increased, only the transgenic cells were able to
maintain a response to the higher dosage.

Proliferative Response Is Dependent Upon Culture Conditions
Splenocytes from each strain (varying MT gene dose) were isolated and
stimulated with lipopolysachharide (LPS) for 36 hours, after which proliferation was
assayed. Cells that had been cultured in a reduced oxygen environment (37 degrees, 10%
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CO2, 7% O2, 83% N2) displayed the same relationship as seen during Concanavalin A
stimulation; the KO splenocytes showed higher levels of proliferation than the MT-TGN
or WT. Yet when cultured under normal oxidative conditions in 5% CO2 (where the
atmosphere consists of a greater amount of oxygen), the MT-TGN cells fared
significantly better than the WT or KO splenocytes. This may indicate that the overexpression of metallothionein confers some protection against a more oxidative
environment because the MT is able to sequester and neutralize harmful reactive species.

20 | Roy-O’Reilly

Discussion
The immune response is a complex cascade of events triggered in response to
many different stressors and antigens. A mechanism this intricate requires precise
regulation that simultaneously allows for recognition and activation against a pathogen
while avoiding an undesirable hyper-reactivity or hypo-reactivity. If metallothionein
plays an important role in immune regulation, then it may provide to be a key therapeutic
target in the treatment of diseases that result from inappropriate immune activation or
suppression, like autoimmune disorders and cancer.
Metallothionein is a stress protein that is known to confer protection against toxic
exposure to metals and oxidizing agents. Yet recent work has shown that MT also plays
an integral role in the regulation of immune response. The experiments described here
were intended to investigate the differences in the immune response caused by different
levels of metallothionein. Proliferation is one of the most important phenomenona of the
early immune response and elucidating the mechanism by which a low gene dose of
metallothionein causes hyper-proliferation of MT-KO spleen cells may help us to better
understand and manipulate these mechanisms.
In conclusion, MTKO cells are primed by their lack of metallothionein to respond
more quickly to polyclonal activation. In addition, over-expression of MT in transgenic
cells may confer protection and augment cellular survival. MT may regulate lymphocyte
responses through several different mechanisms. Metallothionein is known to neutralize
reactive intermediates within the cell. These reactive intermediates are generated by the
ligation of lymphocyte membrane receptors and go on to activate transcription factors. In
an organism with little functional metallothionein, it is possible that the higher threshold
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levels of reactive species cause enhanced transcription factor activation; MT is known to
decrease TNF activation of NF-KB by inhibiting IkB degradation.
MT may also act by regulating the activity of kinases that are necessary for
transcription factor acivity, such as p38 map kinase. MT may also alter transcription my
altering the availability of copper and zinc at the nucleus. The formation of ROS in
lymphocytes may stimulate the release of zinc from metallothionein; the absence of znMT may cause repressors of transcription to remain inactivated, leading to inappropriate
activation and disease states.
Further studies are needed to determine the molecular mechanisms of the MTKO
“primed” response and whether it is due to constant low level oxidative stress (which
cellular metallothionein is believed to reduce in normal cells). Planned experiments
include manipulation of the cellular redox environment with antioxidants, incubation in
different oxidative stress conditions and addition of zinc in order to upregulate MT levels
in mice that can synthesize the protein. We also plan to conduct ELIspot assays of the
three strains in order to quantify the number of active B-cells secreting antibody in the
presence or absence of antioxidant in order to explore the role of oxidant in B-cell
differentiation. Using this data, we endeavor to elucidate the role of endogenous
metallothionein in the suppression of oxidative stress and cellular protection. If we can
characterize the means by which extreme MT levels affect the immune response, it may
enable the development of more targeted therapies that will function to augment innate
immunity and suppress debilitating autoimmune and inflammatory disorders.
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Figures

Figure 1. Experimental Outline. Primary lymphocytes from the three mouse strains
were re-suspended in complete M199 media (5% FBS, .1mM non-essential amino acids,
1 mM sodium pyruvate, 1 mM l-glutamine, 50 ug/ml gentamycine and sodium
bicarbonate) and cell number was determined by a particle counter. They were incubated
at 37 degrees in a special gas mixture (10% CO2, 7% O2, 83% N2) in order to reduce
oxidative stress and prolong cell survival.

Figure 2. Luciferase Reaction. Mono-oxygenation of luciferin catalyzed by luciferase in
the presence of Mg2+, ATP and molecular oxygen.
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Figure 3. 040511 Dosage curve of WT, KO and TG mouse strains treated with
Concanavalin A (ConA). The primary splenocytes isolated C57BL6/J (denoted B6WT), C57BL/6J-TgN(Mt1)174Bri (denoted B6-MTTGN), and C57BL/6JMt1tm1BriMt2tm1Bri (denoted B6-MTKO) mice were cultured in the presence of 5ug/ml (a)
or 10 ug/ml (b ) ConA. The cultures were aliquoted into 96-well plates and incubated at
37 degrees in a reduced oxidative environment. The Cell Titer Glo assay was used to
quantify proliferation at 24h, 48h and 72 hours post-stimulation. RFU= Relative
Fluorescence Units. P < .05 for all points.
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Figure 4. 060611 Dosage curve of WT, KO and TG mouse strains treated with
Concanavalin A (ConA) or Lipopolysaccharide (LPS). The primary splenocytes
isolated C57BL6/J (denoted B6-WT), C57BL/6J-TgN(Mt1)174Bri (denoted B6-MTTGN),
and C57BL/6J-Mt1tm1BriMt2tm1Bri (denoted B6-MTKO) mice were cultured in the
presence of 5ug/ml ConA or LPS. The cultures were aliquoted into 96-well plates and
incubated at 37 degrees in a reduced oxidative environment. The Cell Titer Glo assay was
used to quantify proliferation at 24h post-stimulation. P < .05 for all points.
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Figure 5. 110511. Dosage curve of WT, KO and TG mouse strains treated with LPS
under normal or reduced oxidative culture conditions. The primary splenocytes
isolated C57BL6/J (denoted B6-WT), C57BL/6J-TgN(Mt1)174Bri (denoted B6-MTTGN),
and C57BL/6J-Mt1tm1BriMt2tm1Bri (denoted B6-MTKO) mice were cultured under reduced
oxidative conditions (See Materials and Methods) or normal oxidative conditions in 5%
CO2. The cultures were aliquoted into 96-well plates and incubated at 37 degrees in a
reduced oxidative environment. The Cell Titer Glo assay was used to quantify
proliferation at 24hr post-stimulation. P < .05 for all points.
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